Research Progress of Exosomes in Drug Resistance of Breast Cancer

Overview

Journal Front Bioeng Biotechnol

Date 2024 Jan 19

PMID 38239920

Authors

Lihui Liu

Daqing Jiang

Shi Bai

Xinfeng Zhang

Yue Kang

Affiliations

Soon will be listed here.

Abstract

Since breast cancer is a heterogeneous disease, there are currently a variety of treatment methods available, including chemotherapy, endocrine therapy, molecular targeted therapy, immunotherapy, radiation therapy, etc. Breast cancer recurrence and metastasis, despite many treatment modalities, constitute a considerable threat to patients' survival time and pose a clinical challenge that is difficult to tackle precisely. Exosomes have a very special and crucial role in the treatment of drug resistance in breast cancer as a carrier of intercellular communication in the tumor microenvironment. Exosomes and breast cancer treatment resistance have been linked in a growing number of clinical investigations in recent years. This paper covers the status of research on exosomes in the treatment of breast cancer drug resistance and offers theoretical guidance for investigating new strategies to treat breast cancer drug resistance.

Citing Articles

Exosomes and breast cancer angiogenesis; Highlights in intercellular communication.

Khanicheragh P, Abbasi-Malati Z, Saghebasl S, Hassanpour P, Milani S, Rahbarghazi R Cancer Cell Int. 2024; 24(1):402.

PMID: 39696346 PMC: 11656829. DOI: 10.1186/s12935-024-03606-9.

References

Bigagli E, Cinci L, DAmbrosio M, Luceri C . Transcriptomic Characterization, Chemosensitivity and Regulatory Effects of Exosomes in Spontaneous EMT/MET Transitions of Breast Cancer Cells. Cancer Genomics Proteomics. 2019; 16(3):163-173. PMC: 6542641. DOI: 10.21873/cgp.20122. View

Rashid N, Grible J, Clevenger C, Harrell J . Breast cancer liver metastasis: current and future treatment approaches. Clin Exp Metastasis. 2021; 38(3):263-277. PMC: 8211035. DOI: 10.1007/s10585-021-10080-4. View

Semina S, Scherbakov A, Vnukova A, Bagrov D, Evtushenko E, Safronova V . Exosome-Mediated Transfer of Cancer Cell Resistance to Antiestrogen Drugs. Molecules. 2018; 23(4). PMC: 6017149. DOI: 10.3390/molecules23040829. View

Sedgwick A, DSouza-Schorey C . The biology of extracellular microvesicles. Traffic. 2018; 19(5):319-327. PMC: 6922305. DOI: 10.1111/tra.12558. View

Cortesi L, Toss A, Cirilli C, Marcheselli L, Braghiroli B, Sebastiani F . Twenty-years experience with de novo metastatic breast cancer. Int J Cancer. 2015; 137(6):1417-26. DOI: 10.1002/ijc.29503. View

Han M, Hu J, Lu P, Cao H, Yu C, Li X . Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer. Cell Death Dis. 2020; 11(1):43. PMC: 6976584. DOI: 10.1038/s41419-020-2250-5. View

Aqil F, Munagala R, Jeyabalan J, Agrawal A, Gupta R . Exosomes for the Enhanced Tissue Bioavailability and Efficacy of Curcumin. AAPS J. 2017; 19(6):1691-1702. DOI: 10.1208/s12248-017-0154-9. View

Taube J, Galon J, Sholl L, Rodig S, Cottrell T, Giraldo N . Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2017; 31(2):214-234. PMC: 6132263. DOI: 10.1038/modpathol.2017.156. View

Bardelli A, Pantel K . Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell. 2017; 31(2):172-179. DOI: 10.1016/j.ccell.2017.01.002. View

10.

Stevic I, Muller V, Weber K, Fasching P, Karn T, Marme F . Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018; 16(1):179. PMC: 6178264. DOI: 10.1186/s12916-018-1163-y. View

11.

Li R, Chibbar R, Xiang J . Novel EXO-T vaccine using polyclonal CD4 T cells armed with HER2-specific exosomes for HER2-positive breast cancer. Onco Targets Ther. 2018; 11:7089-7093. PMC: 6200095. DOI: 10.2147/OTT.S184898. View

12.

Ahmad A . Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers. Adv Exp Med Biol. 2019; 1152:217-228. DOI: 10.1007/978-3-030-20301-6_10. View

13.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

14.

Nedeljkovic M, Damjanovic A . Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019; 8(9). PMC: 6770896. DOI: 10.3390/cells8090957. View

15.

Meldolesi J . Exosomes and Ectosomes in Intercellular Communication. Curr Biol. 2018; 28(8):R435-R444. DOI: 10.1016/j.cub.2018.01.059. View

16.

Liu X, Zhang G, Yu T, Liu J, Chai X, Yin D . CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy. Int J Biol Macromol. 2023; 250:126147. DOI: 10.1016/j.ijbiomac.2023.126147. View

17.

Yang B, Peng F, Zhang Y, Wang X, Wang S, Zheng Y . Aiduqing formula suppresses breast cancer metastasis via inhibiting CXCL1-mediated autophagy. Phytomedicine. 2021; 90:153628. DOI: 10.1016/j.phymed.2021.153628. View

18.

Scherbakov A, Andreeva O, Shatskaya V, Krasilnikov M . The relationships between snail1 and estrogen receptor signaling in breast cancer cells. J Cell Biochem. 2012; 113(6):2147-55. DOI: 10.1002/jcb.24087. View

19.

Ozawa P, Alkhilaiwi F, Cavalli I, Malheiros D, Ribeiro E, Cavalli L . Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat. 2018; 172(3):713-723. PMC: 6245099. DOI: 10.1007/s10549-018-4925-5. View

20.

Campos A, Burgos-Ravanal R, Lobos-Gonzalez L, Huilcaman R, Gonzalez M, Diaz J . Caveolin-1-dependent tenascin C inclusion in extracellular vesicles is required to promote breast cancer cell malignancy. Nanomedicine (Lond). 2023; 18(23):1651-1668. DOI: 10.2217/nnm-2023-0143. View